Clinical trial · Observational
Kidney and Blood Pressure Changes in Patients Receiving Bevacizumab, Aflibercept, Sunitinib, or Cediranib for Cancer
The Role of VEGF-A Signaling in Maintenance of the Glomerular Filtration Barrier and Blood Pressure
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research study is looking at kidney and blood pressure changes in patients receiving bevacizumab, aflibercept, sunitinib, or cediranib for cancer. Studying samples of blood and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment with an antiangiogenic drug.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Renal and blood pressure changes
- timeFrame
- Up to 8 weeks
- measure
- Physiological mechanism behind proteinuria and hypertension induced by antiangiogenic therapies
- timeFrame
- Up to 8 weeks
- measure
- Predictive value of soluble factors in the development of proteinuria or hypertension
- timeFrame
- Up to 8 weeks
- measure
- Predictive value of steady state drug concentrations in the development of proteinuria or hypertension
- timeFrame
- Up to 8 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Planning to start treatment with one of the following antiangiogenic drugs as single agents or in combination with chemotherapy for their cancer: * Cediranib (AZD2171 ) * Bevacizumab (Avastin) * Sunitinib (Sutent) * Aflibercept (VEGF Trap) * Urinalysis negative for protein OR 24-hour urine for protein \< 500 mg * Prior chemotherapy within the past 12 months allowed * More than 12 months since prior antiangiogenic drugs, including monoclonal antibodies that bind to VEGF or tyrosine kinase inhibitors that block VEGFR2 * At least 6 weeks since prior and no concurrent aldosterone receptor antagonists (e.g., spironolactone \[aldactone\] or eplerenone) * No other concurrent investigational agents
References
Publications (0)
Data not yet available